Companies: 10,795·Total market cap: $144.5T
Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

DRUGNASDAQHealthcare● Active
$67.27
$-1.73(-2.51%)
Market Cap$522117114
P/E Ratio—
52W High$123.75
52W Low$23.175
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Bright Minds Biosciences Inc. (DRUG) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001827401 · DRUG · NASDAQ · as of Jun 8, 2026

Filing snapshot

172
Total Filings
6-K
Latest Form
2026-06-03
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001827401 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2024-12-31
Fiscal Year End
Dec 31, 2024
Accession No.
0001062993-24-021301
Primary Document
form20f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001827401 · Accession 0001062993-24-021301

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2026-06-03
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-06-03
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-06-02
View
6-KCurrent Report (Foreign Issuer)
Current Report (Foreign Issuer)
2026-05-28
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-05-20
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-12
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-30
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-02-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-06
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-01-09
View
Showing 1–15 of 169 filingsForm 4 / 144 hidden· 172 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001827401  |  Exchange: NASDAQ · Healthcare

Bright Minds Biosciences Inc. (NASDAQ: DRUG) has submitted 172 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001827401, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Bright Minds Biosciences Inc.'s most comprehensive regulatory disclosure. The most recent Bright Minds Biosciences Inc. 10-K was filed on 2024-12-31 for fiscal year ending 2024. Historical DRUG 10-K annual reports are available from 2020 through 2024.

Investors researching Bright Minds Biosciences Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
LBRX SEC Filings →DSGN SEC Filings →ANNX SEC Filings →AURA SEC Filings →DMAC SEC Filings →ALT SEC Filings →IMAB SEC Filings →GALT SEC Filings →
→ DRUG Financials→ DRUG Earnings→ DRUG Insider Trades

Frequently Asked Questions

DRUG SEC Filings · 8 questions

Bright Minds Biosciences Inc. (DRUG) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 172 filings and access original documents at no cost. Bright Minds Biosciences Inc.'s CIK is 0001827401.

DRUG SEC filingsBright Minds Biosciences Inc. SEC documentsfind DRUG 10-K